ClinicalTrials.gg

Program

tecotabart vedotin

Also written as “LM-302” and “LM-302 Injection”.

In Sino Biopharmaceutical's pipeline, Claudin18.2 ADC. Its studies are mostly in Adenocarcinoma, led by 2 companies.

Furthest: phase 3, since Mar 15, 20246 company-led studies, 3 open or runningNext primary completion: Oct 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical53 open or runningphase 3since Mar 15, 2024Dec 5, 2021Oct 2028phase 3 · NCT07385703
Bristol-Myers Squibb10 open or runningphase 1since Jul 27, 2021Jul 27, 2021none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as LM-302, phase 3, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2021First study: phase 1 study in Advanced Solid TumorNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT05001516 · 17 enrolled · United States
  2. Dec 5, 2021Sino Biopharmaceutical's first studies: 2 phase 2 studies in Advanced Solid TumorNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05161390, NCT05188664
  3. Jun 19, 2023Phase 2 study in Malignant Neoplasms of Digestive OrgansSino Biopharmaceutical · NCT05934331 · 632 planned · China
  4. Mar 15, 2024Phase 3 study in Locally Advanced or Metastatic GC and GCJ AdenocarcinomaSino Biopharmaceutical · NCT06351020 · 387 enrolled · China
  5. Jan 25, 2026Phase 3 study in AdenocarcinomaSino Biopharmaceutical · NCT07385703 · 752 planned · China
  6. Oct 19, 2026Primary completion moved from 2026-07-01 to 2031-08-06Date moved laterphase 2 · +61 months · NCT05934331

Ahead

  1. Nov 10, 2026Primary completion: phase 3 study in Locally Advanced or Metastatic GC and GCJ AdenocarcinomaSino Biopharmaceutical · NCT06351020
  2. Oct 2028Primary completion: phase 3 study in AdenocarcinomaSino Biopharmaceutical · NCT07385703
  3. Aug 6, 2031Primary completion: phase 2 study in Malignant Neoplasms of Digestive OrgansSino Biopharmaceutical · NCT05934331

TargetBeta

“Claudin18.2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07385703Adenocarcinoma · China3RecruitingSino BiopharmaceuticalOct 2028752
NCT06351020Locally Advanced or Metastatic GC and GCJ Adenocarcinoma · China3Active, not recruitingSino BiopharmaceuticalNov 10, 2026387
NCT05934331Malignant Neoplasms of Digestive Organs · China2RecruitingSino BiopharmaceuticalAug 6, 2031632
NCT05188664Advanced Solid Tumor · Australia2CompletedSino BiopharmaceuticalNov 14, 202320
NCT05161390Advanced Solid Tumor · China2CompletedSino BiopharmaceuticalJan 10, 2025153
NCT05001516Advanced Solid Tumor · United States1CompletedBristol-Myers SquibbJan 4, 202417

How it is read

Names in the registry

  • “LM-302”, 5 entries
  • “LM-302 Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.